RESULTS:
A total of 45,179 pregnancies resulting in delivery of a live or stillborn infant were documented at The Ottawa Hospital during the study period. Our findings indicate that 0.124%, or 1240 in 1,000,000, expectant mothers received transfusion at some point during their pregnancies with 0.04%, or 400 per 1,000,000, expectant mothers receiving a transfusion in the first trimester.
CONCLUSION: Data from a large tertiary care center suggest that the risk of maternal and fetal exposure to blood products by transfusion during any stage of pregnancy is very low. Such a low likelihood of transfusion should be taken into consideration when developing donor deferral policies designed to protect women against transfusion-associated infection transmission during pregnancy and could inform evaluations of the risk of prenatal transfusion transmission of the Zika virus.
T ransfusion-transmitted viral infections can be a significant risk to pregnant populations. In the past this has included hepatitis viruses, human immunodeficiency virus, cytomegalovirus (CMV), human parvovirus B19, 1 and, more recently, Dengue virus 2, 3 and Zika virus. 4, 5 The current Zika virus outbreak in particular, has forced an examination of the risk of exposure to blood products during pregnancy. In 2016, the mosquito-borne Zika virus emerged as a major public health issue, with the World Health Organization declaring it a worldwide public health emergency on February 1, 2016. 6 As of December 2016 the virus had spread across 69 countries worldwide. 7 Of considerable concern is the association between maternal exposure to Zika virus and severe congenital neurological consequences to infants born to infected mothers. Indeed, an increase in the number of cases of microcephaly in Brazil has been noted in association with the 2016 outbreak, 8 and as this manuscript goes to press women who are either currently pregnant or contemplating pregnancy are advised to avoid travel to high-risk areas. 9 Widespread concern regarding potential viral transmission has prompted blood agencies to actively seek optimal deferral or testing strategies to protect blood supplies-particularly to ensure the protection of pregnant women and their unborn infants. 4, 5 In the most recent 2016 Zika outbreak three cases of transfusion transmission have thus far been docmented. 5, 10, 11 As of December 29th 2016 roughly 22 countries and territories in the Americas had reported cases of microcephaly and/or other congenital neurological anomalies associated with Zika virus infection, 9 although to our knowledge there have been no known cases of maternal-fetal Zika virus transmission as a result of exposure to infected blood products.
In an effort to provide instructive data to authorities seeking to optimally protect pregnant women from the potential transfusion transmission of the Zika virus and other infectious threats, this study aims to examine the risk of exposure to transfusion products in the pregnant population using routinely collected administrative data from a large tertiary care center. Specifically, we sought to determine the likelihood of receiving a transfusion across all stages of pregnancy.
MATERIALS AND METHODS

Study design
This was a retrospective, observational study of obstetric patients admitted for delivery to The Ottawa Hospital. The Ottawa Hospital is one of Canada's largest academic health sciences centers, serving in excess of 1.3 million residents across Eastern Ontario, Canada. There are more than 6000 deliveries annually, accounting for approximately 4.75% of births in the province of Ontario and 44.5% of the births in the Champlain Local Health Integration Network. The Ottawa Hospital's Data Warehouse is a large data repository for the hospital's information systems that includes the hospital's administrative, laboratory, and discharge abstract information databases. The Data Warehouse is optimally structured for transfusion research, permitting identification of transfusion recipients, and tracking their use of hospital services and health outcomes.
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Sample population
Both inpatient and outpatient transfusions were considered. The Data Warehouse's Discharge Abstract Database was used to identify all women admitted under acute care obstetric services at any campus of The Ottawa Hospital. Pregnancies resulting in newborn delivery, including stillbirth, over the 7-year period between January 1, 2007, and December 31, 2013, were included. Cases with missing gestational age information were excluded from analysis ( Fig. 1) . Pregnancies for which at least one blood transfusion (red blood cells [RBCs] , platelets [PLTs], or plasma products) was administered during a nondelivery admission or outpatient hospital visit during pregnancy were determined through analysis of the Discharge Abstract Database, Blood Product Tables, Shared Medical Systems, and Open Architect Clinical Information System. RBC products included packed RBCs and washed RBCs; PLT products included apheresis and buffy coat-derived PLTs; and plasma products included frozen plasma (not subjected to any pathogen reduction technology) and cryosupernatant plasma. Blood products which undergo viral inactivation processes, including intravenous immunoglobulins, albumin, and antithrombins were not included for analysis. Pathogen transmission is of concern for blood products that do not undergo pathogen inactivation. In Canada, these products are all RBC and PLT products, as well as most plasma components. There were no recipients of cryoprecipitate, fresh-frozen plasma, or solvent/ detergent-treated plasma in the cohort. Approval for this study was granted by the Ottawa Hospital Science Network Research Ethics Board, Protocol 20120280-01H.
Statistical analysis
Women receiving a transfusion were reported as a percentage of all women delivering at an acute care obstetric service at The Ottawa Hospital. The median and interquartile ranges (IQRs) of number of units transfused per patient are reported by trimester of pregnancy for transfusion products overall, as well as by product (RBCs, PLTs, or plasma).
RESULTS
A total of 45,179 pregnancies resulting in delivery of a live or stillborn infant were documented at The Ottawa Hospital for between January 1, 2007, and December 31, 2013. Overall, at least one transfusion was documented for 56 of the 45,179 pregnancies (0.124%, or one in 1240 pregnancies): 52 (0.115%) receiving RBCs, five (0.011%) receiving PLTs, and two (0.004%) receiving plasma.
Transfusion patterns by trimester of pregnancy
In the first trimester of pregnancy, 18 (0.040%) women received blood product transfusions-RBC units were administered to 15 (0.033%) women, PLT units to two (0.004%) women, and plasma units to one (0.002%) woman. Second-trimester transfusion occurred in 34 (0.075%) women-33 (0.073%) women received RBC units and one (0.002%) and two (0.004%) women received PLTs and plasma, respectively. Third-trimester transfusions were administered to 28 (0.063%) women-25 (0.056%) women received RBC units, three (0.007%) women received PLTs, and one (0.002%) woman received plasma products.
Of those transfused, 32.1% of women received transfusions in the first trimester, 60.7% in the second trimester, and 50.0% in the third trimester. RBCs were the most commonly transfused products, occurring in 52 of the 56 women who received transfusions (92.86%). Of those women receiving transfusions, 15 (26.78%) received RBC units in the first trimester, 33 (58.93%) in the second trimester, and 25 (44.64%) in the third trimester. Of note, of those women who received transfusions during pregnancy, 32 (57.1%) received transfusion once during their pregnancies, whereas 24 (42.9%) experienced two or more transfusion events. The distribution of transfusions by trimester of pregnancy is provided in Table 1 .
Volume of blood product transfused per transfused patient
A total of 434 transfusion units were administered during the study period. A total of 349 RBC units were delivered-76 (19.8%) in the first trimester, 164 (49.0%) in the second trimester, and 109 (31.2%) in the third trimester. The median numbers of RBC units delivered per patient were greatest in the third trimester of pregnancy, at 3 (IQR, 2-6) units. A total of 13 PLT units were transfused-2 (15.4%) in the first trimester, 8 (61.5%) in the second trimester, and 3 (23.1%) in the third trimester. Seventy-two plasma units were administered over the study period-19 (26.4%) in the first trimester, 43 (59.7%) in the second trimester, and 10 (13.9%) in the third trimester. Median PLT and plasma units transfused per patient were both greatest in the second trimester; 8 (IQR, 8-8) and 22 (4-39) units, respectively. A summary of units transfused per patient for any blood product and RBCs, PLTs, and plasma units specifically is provided in Table 2 .
DISCUSSION
Our data suggest that the risk of maternal and fetal exposure to blood products by transfusion during any stage of pregnancy is very low. Through retrospective examination of a large tertiary care hospital-based cohort of 45,179 patients, we found that 0.124%, or 1240 in 1,000,000, of expectant mothers are transfused at some point during their pregnancies, with 0.04%, or 400 per 1,000,000, of expectant mothers receiving a transfusion in the first trimester. Not unexpectedly, RBCs were the most commonly transfused products, overall, with volume of RBCs delivered per patient greatest in the third trimester.
For this study, only nondelivery admissions or hospital outpatient encounters were assessed, as transfusion during a delivery admission would not affect congenital development. Timing of transfusions is important when considering impact of infection transmission to the course of pregnancy and development of the fetus. Indeed, in the context of Zika virus, our current understanding is that risk of microcephaly due to Zika virus infection is highest in the earliest stages of pregnancy, specifically the first trimester. 15, 16, 23 Although transfusion patterns in our cohort may not be representative of those at other clinical centers, including those in other international jurisdictions, these data stem from a large tertiary referral center for high-risk pregnancies. Thus, the data presented here likely provide an overestimation for the risk of transfusion, compared to pregnancies followed in community hospitals. A significant strength of our study is the inclusion of all transfusions given to expectant mothers in both the inpatient and the outpatient setting, over a 6-year period of time. Blood centers have long been striving to implement riskbased decision making to maintain both the safety and the adequacy of the blood supply in the face of various challenges, including emerging pathogens. 17 As this often includes risk modeling, the quality of data for various variables will ultimately influence the accuracy of the model. Our study illustrates the value of using readily available large transfusion databases to determine transfusion rates in particular risk populations, such as expectant mothers. Data on the frequency of transfusion to expectant mothers may also be useful for assessment of other donor criteria, such as the benefit of long-term donor deferrals for use of teratogenic medications and donor testing strategies such as the utility of CMV testing of blood components. The use of such large population data sets is expected to increase in transfusion medicine. 18 In the case of the 2016 Zika virus outbreak, since the mosquito species known to transmit the virus are not currently present in Canada, policy development has focused on risk modeling of donor travel, likely viremic period, and likelihood of transfusion to high-risk recipients, namely, expectant mothers. 19 In When considering the risk of potential viral transmission via infected blood products, blood systems consider not only risks of maternal infection but also the risk of infection to the general population. However, as it pertains to the pregnant population, our findings are reassuring in that the risk of maternal exposure to blood products throughout pregnancy is extremely low. When considering regional donor deferral policies, the low proportion of women (0.124%) receiving a transfusion at any stage in pregnancy needs to be considered alongside a required concomitance of other factors to elicit unfavorable effects on the course of pregnancy and severe lasting effects in the newborn. Such considerations include the probability of maternal-to-child transmission resulting in stillbirth and congenital or neurologic defects (in the case of Zika virus, this risk has been reported to be highest or limited to the first trimester) 15, 16, 23 the likelihood that a mother will actually be infected as a result of infected product transfusion, and the likelihood of the transfused blood product harboring the virus. In summary, with a very low likelihood of maternal blood product exposure and current deferral policies in place, introduction of additional mechanisms to mitigate risk of viral transmission through maternal transfusion should be carefully considered. Our findings are instructive as deferral and screening policies evolve to address emerging public health challenges and the transfusion transmission of these to pregnant women. 
